Migraine is a highly disabling neurological disorder that directly affects more than 1 billion
individuals worldwide. Available treatment options differ between countries and include …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …

Background In this study, we aimed to evaluate the efficacy, safety, and tolerability of
atogepant for the preventive treatment of chronic migraine. Methods We did this randomised …

Importance Approximately 90% of people in the US experience headache during their
lifetime. Migraine is the second leading cause of years lived with disability worldwide …

Background Switching between antibody classes might be a treatment option in migraine
patients who have not responded to one class of a CGRP-(receptor) monoclonal antibody …

Regular or frequent use of analgesics and acute antimigraine drugs can increase the
frequency of headache, and induce the transition from episodic to chronic headache or …

Clinical trials are a key component of the evidence base for the treatment of headache
disorders. In 1991, the International Headache Society Clinical Trials Standing Committee …

Background Clinical trials have shown the safety and clinical superiority of erenumab
compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the …

Background We aimed to assess the efficacy and safety of erenumab, a fully human
monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …